Barrington Research Rates Lifecore Biomedical (LFCR) buy
Barrington Research maintains its buy rating on LFCR with a price target of $6.50, a 17.33% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Barrington Research rated Lifecore Biomedical, Inc. ($LFCR) "buy" with a $6.50 price target on June 16, 2026.
Since the rating, $LFCR is up 5.8% after 1 week, down 7.5% after 1 month and up 19.2% to date (from the $5.35 close on Jun 16, 2026).
LFCR
Lifecore Biomedical, Inc.
Key Points
- Barrington Research reiterated its buy rating on LFCR, setting a price target of $6.50 on June 16, 2026.
- Barrington Research's $6.50 price target implies 17.33% upside from Lifecore Biomedical, Inc.'s ($LFCR) current $5.54 share price.
- LFCR shares recently traded at $5.49, with insider buying activity recorded on June 4, 2026.
- Peers like BlackRock and Greenhaven Road adjusted their LFCR positions, while Vanguard initiated a new stake.
Get $LFCR trade alerts by text
We text you when insiders, Congress or big funds trade $LFCR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Lifecore Biomedical, Inc. alert may contain errors. Disclosures
Barrington Research has reiterated its buy rating on LFCR, setting a new price target of $6.50. This update came on June 16, 2026, as the stock traded around $5.49.
Other Institutional Activity in LFCR
Wynnefield Capital Inc held steady with 4,703,216 shares valued at about $17.5 million. Legion Partners Asset Management LLC also maintained its position with 4,461,823 shares worth roughly $16.6 million. Meanwhile, Greenhaven Road Investment Management, L.P. trimmed its holdings by 145,000 shares, ending with 3,537,573 shares valued at approximately $13.2 million. BlackRock, Inc. reduced its stake by 29,779 shares, bringing its total to 1,877,305 shares, valued at around $6.98 million. In contrast, Vanguard Capital Management LLC initiated a new position with 1,290,136 shares valued at about $4.8 million.
Lifecore Biomedical, Inc. Stock Up 24.2%
LFCR shares are currently trading near $5.49. The stock has seen various institutional movements, reflecting different strategies among investors.
$LFCR price target
Lifecore Biomedical, Inc. daily closes and this analyst's $6.50 target. Not advice.
Insider Buying and Selling at Lifecore Biomedical, Inc.
On June 4, 2026, several insiders, including Christopher Kiper, Matthew Korenberg, Humberto Calheiros Antunes, Katrina Houde Lovas, Nelson Obus, and Paul Harold Johnson, each bought 25,907 shares. These transactions were not part of any pre-planned trading scheme.
Analysts Set New Price Targets
On June 16, 2026, Barrington Research maintained its buy rating on LFCR, setting a price target of $6.50. Previously, on April 29, 2026, the firm had set a $6.00 target, and in March, it had a target of $5.50. Stephens & Co. reiterated a hold rating with a $6.00 target back in January 2025, while Craig-Hallum maintained a buy rating with a $10.00 target in November 2024.
Bottom Line
Barrington Research's reiterated buy rating and updated price target suggest confidence in LFCR's potential. With insider buying and varied institutional activity, LFCR remains a stock to watch. Remember, these analyst ratings are backward-looking and may not reflect current market conditions.
Related Filing Alerts
Source: Barrington Research's rating change on $LFCR (Jun 16, 2026). Written by software, not financial advice. How we make alerts